Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s391769
Abstract: Background To date, no study evaluated the cost-effectiveness of palbociclib (PAL) plus fulvestrant (FUL) vs ribociclib (RIB) plus FUL and abemaciclib (ABM) plus FUL in Italy. Cost-effectiveness analysis comparing the three cyclin-dependent 4/6 kinase inhibitors… read more here.
Keywords: cost; breast cancer; effectiveness; plus ful ... See more keywords